Elizabeth Stankevich

6.0k total citations · 1 hit paper
39 papers, 2.9k citations indexed

About

Elizabeth Stankevich is a scholar working on Oncology, Epidemiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Elizabeth Stankevich has authored 39 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 14 papers in Epidemiology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Elizabeth Stankevich's work include Cancer Immunotherapy and Biomarkers (29 papers), CAR-T cell therapy research (18 papers) and Nonmelanoma Skin Cancer Studies (14 papers). Elizabeth Stankevich is often cited by papers focused on Cancer Immunotherapy and Biomarkers (29 papers), CAR-T cell therapy research (18 papers) and Nonmelanoma Skin Cancer Studies (14 papers). Elizabeth Stankevich collaborates with scholars based in United States, Spain and Australia. Elizabeth Stankevich's co-authors include Israel Lowy, Drew M. Pardoll, Charles G. Drake, Joel Picus, John D. Powderly, Suzanne L. Topalian, Ira Wollner, Julie R. Brahmer, Alan J. Korman and Alice Pons and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Elizabeth Stankevich

38 papers receiving 2.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

2010 2.3k citations Julie R. Brahmer, Charles G. Drake et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elizabeth Stankevich United States	15	2.4k	1.3k	665	416	337	39	2.9k
Wen‐Jen Hwu United States	27	2.5k 1.0×	1.0k 0.8×	780 1.2×	1.1k 2.6×	168 0.5×	92	3.2k
Alexander N. Shoushtari United States	34	3.3k 1.4×	1.6k 1.2×	833 1.3×	1.4k 3.4×	286 0.8×	167	4.7k
Rom S. Leidner United States	27	2.4k 1.0×	1.5k 1.1×	576 0.9×	965 2.3×	270 0.8×	94	3.7k
Josep M. Piulats Spain	30	1.5k 0.6×	894 0.7×	847 1.3×	1.1k 2.6×	303 0.9×	162	3.2k
Yutaka Kawakami Japan	22	915 0.4×	681 0.5×	409 0.6×	777 1.9×	553 1.6×	37	2.4k
Emma C. Scott United States	10	2.3k 0.9×	1.3k 1.0×	346 0.5×	661 1.6×	357 1.1×	27	3.2k
Alexander Guminski Australia	30	3.1k 1.3×	860 0.7×	1.2k 1.9×	1.1k 2.7×	679 2.0×	114	4.2k
David Gyorki Australia	22	2.1k 0.9×	577 0.4×	459 0.7×	1.2k 2.8×	246 0.7×	109	3.0k
Alice Pons United States	5	2.4k 1.0×	1.3k 1.0×	668 1.0×	411 1.0×	119 0.4×	8	2.8k
Kent C. Shih United States	19	1.7k 0.7×	420 0.3×	509 0.8×	611 1.5×	308 0.9×	54	2.6k

Countries citing papers authored by Elizabeth Stankevich

Since Specialization

Citations

This map shows the geographic impact of Elizabeth Stankevich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth Stankevich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth Stankevich more than expected).

Fields of papers citing papers by Elizabeth Stankevich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth Stankevich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth Stankevich. The network helps show where Elizabeth Stankevich may publish in the future.

Co-authorship network of co-authors of Elizabeth Stankevich

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth Stankevich. A scholar is included among the top collaborators of Elizabeth Stankevich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth Stankevich. Elizabeth Stankevich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brahmer, Julie R., Charles G. Drake, Ira Wollner, et al.. (2023). Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates. Journal of Clinical Oncology. 41(4). 715–723. 31 indexed citations

Moreno, Víctor, Pilar Garrido, Kyriakos P. Papadopoulos, et al.. (2021). Tolerability and antitumor activity of cemiplimab, a human monoclonal anti–PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort. Lung Cancer. 155. 151–155. 11 indexed citations

Paccaly, Anne, Michael R. Migden, Kyriakos P. Papadopoulos, et al.. (2021). Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis. Advances in Therapy. 38(5). 2365–2378. 8 indexed citations

Papadopoulos, Kyriakos P., Melissa L. Johnson, A. Craig Lockhart, et al.. (2019). First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies. Clinical Cancer Research. 26(5). 1025–1033. 50 indexed citations

Migden, Michael R., Nikhil I. Khushalani, Anne Lynn S. Chang, et al.. (2019). Primary analysis of phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC).. Journal of Clinical Oncology. 37(15_suppl). 6015–6015. 24 indexed citations

Rischin, Danny, Nikhil I. Khushalani, Chrysalyne D. Schmults, et al.. (2019). Impact of Prior Lines of Systemic Therapy (PST) on the Efficacy Of Cemiplimab, a Human Monoclonal Anti–PD-1, in Patients (PTS) with Advanced Cutaneous Squamous Cell Carcinoma (CSCC). Annals of Oncology. 30. xi35–xi36.

Migden, Michael R., Anne Paccaly, Kyriakos P. Papadopoulos, et al.. (2019). Pharmacokinetic (PK) analysis of weight-based and fixed dose cemiplimab in patients (pts) with advanced malignancies. Annals of Oncology. 30. v520–v520. 3 indexed citations

Moreno, Víctor, Emiliano Calvo, Marta Gil-Martín, et al.. (2018). Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, in patients with non-small cell lung cancer (NSCLC): Interim data from phase 1 dose escalation and NSCLC Expansion Cohort.. Journal of Clinical Oncology. 36(15_suppl). e21057–e21057. 3 indexed citations

Moreno, Víctor, Marta Gil-Martín, Melissa L. Johnson, et al.. (2018). MA04.01 Cemiplimab, a Human Monoclonal Anti-PD-1, Alone or in Combination with Radiotherapy: Phase 1 NSCLC Expansion Cohorts. Journal of Thoracic Oncology. 13(10). S366–S366. 14 indexed citations

10.

Moreno, Víctor, Marta Gil-Martín, Melissa L. Johnson, et al.. (2018). Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2). Annals of Oncology. 29. viii414–viii414. 3 indexed citations

11.

He, Aiwu Ruth, Glen J. Weiss, Gerald S. Falchook, et al.. (2018). Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort (EC) in a phase I study. Annals of Oncology. 29. x26–x26. 8 indexed citations

12.

Lewis, Karl D., Matthew G. Fury, Elizabeth Stankevich, et al.. (2018). Phase II study of cemiplimab, a human monoclonal anti-PD-1, in patients with advanced basal cell carcinoma (BCC) who experienced progression of disease on, or were intolerant of prior hedgehog pathway inhibitor (HHI) therapy. Annals of Oncology. 29. viii440–viii440. 2 indexed citations

13.

Babiker, Hani M., Irene Braña, Daruka Mahadevan, et al.. (2018). Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Annals of Oncology. 29. viii418–viii418. 1 indexed citations

14.

Owonikoko, Taofeek K., Kyriakos P. Papadopoulos, Melissa L. Johnson, et al.. (2018). Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Final efficacy and safety data.. Journal of Clinical Oncology. 36(15_suppl). 9557–9557. 8 indexed citations

15.

Papadopoulos, Kyriakos P., Taofeek K. Owonikoko, Melissa L. Johnson, et al.. (2017). REGN2810: A fully human anti-PD-1 monoclonal antibody, for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)—Initial safety and efficacy from expansion cohorts (ECs) of phase I study.. Journal of Clinical Oncology. 35(15_suppl). 9503–9503. 18 indexed citations

16.

Falchook, Gerald S., Rom S. Leidner, Elizabeth Stankevich, et al.. (2016). Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. Journal for ImmunoTherapy of Cancer. 4(1). 70–70. 109 indexed citations

17.

Brahmer, Julie R., Charles G. Drake, Ira Wollner, et al.. (2010). Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates. Journal of Clinical Oncology. 28(19). 3167–3175. 2331 indexed citations breakdown →

18.

Gerritsen, W.R., Alfons J. van den Eertwegh, Tanja D. de Gruijl, et al.. (2007). Biochemical and immunologic correlates of clinical response in a combination trial of the GM-CSF-gene transduced allogeneic prostate cancer immunotherapy and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHRPC). Journal of Clinical Oncology. 25(18_suppl). 5120–5120. 15 indexed citations

19.

Stankevich, Elizabeth, et al.. (1999). Biokinetics of gidazepam, derivatives of peptideaminobenzophenones and their metabolites. Experimental and Toxicologic Pathology. 51(4-5). 451–454. 4 indexed citations

20.

Андронати, С. А., et al.. (1992). Biokinetics of a new protodrug hydazepam and its metabolite. Bulletin of Experimental Biology and Medicine. 113(1). 63–66. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact